Roche has received FDA clearance for its Elecsys® pTau217 blood test, marking a significant advancement in Alzheimer's disease assessment. Designed for individuals aged 55 and older who are experiencing signs or symptoms of cognitive decline, the test helps clinicians identify amyloid pathology, a key hallmark of Alzheimer's disease. Developed in collaboration with Eli Lilly and Company, it is the first FDA-cleared single-biomarker blood test that supports both ruling in and ruling out amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings.
The clearance addresses a critical need in Alzheimer's care, as many people living with dementia remain undiagnosed or experience lengthy delays before receiving a diagnosis. Traditional diagnostic tools such as PET scans and cerebrospinal fluid testing can be costly, invasive, and difficult to access. Roche's blood-based test offers a less invasive alternative that can be integrated into existing laboratory workflows, potentially helping healthcare providers identify individuals who may require additional evaluation or specialist referral earlier in the diagnostic journey.
The test can be run on Roche's existing network of more than 4,500 cobas® laboratory instruments across the United States, supporting broad implementation and accessibility. By expanding access to blood-based Alzheimer's testing in both primary and specialty care, Roche aims to help improve diagnostic efficiency, reduce barriers to assessment, and support more timely care for patients and their families.
Learn more about the FDA clearance of Elecsys® pTau217 and the company's ongoing efforts to advance Alzheimer's disease diagnosis and care.
